Irene Kang, MD
Medical Oncology · Irvine, CANPI 1336430727
Payments from drug & device makers
Across 167 payments — averaging $7204.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$393K
- Pfizer$279K
- Puma Biotechnology, Inc.$182K
- Merck$143K
- AstraZeneca$136K
- E.r. Squibb & Sons, L.L.C.$30K
- plus $40K from 10 others
What the payments were for
- Consulting fees$43,58372%
- Speaking & faculty fees$10,97018%
- Travel & lodging$2,3924%
- Food & beverage$3,4836%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 25 | $392,908 |
| Pfizer | 16 | $279,083 |
| Puma Biotechnology, Inc. | 34 | $182,246 |
| Merck | 2 | $143,368 |
| AstraZeneca | 7 | $135,677 |
| E.r. Squibb & Sons, L.L.C. | 10 | $30,083 |
| Daiichi Sankyo Inc. | 21 | $15,137 |
| AbbVie(2 entities) | 3 | $10,228 |
| Gilead | 26 | $7,568 |
| Stemline Therapeutics Inc. | 6 | $3,443 |
| Novartis | 9 | $2,561 |
| Caris MPI, Inc. | 2 | $390 |
| Genentech, Inc. | 1 | $150 |
| Incyte Corporation | 1 | $122 |
| Amgen | 3 | $118 |
| Genentech USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,203,099 in reported general payments places this provider in the 80th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 26 | $343,102 |
| TukysaTucatinib | 13 | $317,096 |
| Exemestane | 35 | $6,858 |
| Letrozole | 65 | $1,871 |
| Anastrozole | 50 | $948 |
| Tamoxifen Citrate | 24 | $455 |
| Prochlorperazine Maleate | 11 | $98 |
| Ondansetron Hcl | 14 | $62 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Irvine
- Pashtoon KasiIrvine$3.1M
- Sarmad SadeghiLos Angeles$26.1M
- Marwan FakihDuarte$24.2M
- Sumanta PalDuarte$15.9M
- Farshid DayyaniOrange$13.4M
- Daneng LiDuarte$12.4M
- Heinz-Josef LenzLos Angeles$11.6M
- Kevin KimSan Francisco$10.8M
- Anthony El-KhoueiryLos Angeles$10.5M
- Amy ChienSan Francisco$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.